<DOC>
	<DOCNO>NCT01146795</DOCNO>
	<brief_summary>This study determine feasibility administer neoadjuvant carboplatin , paclitaxel , bevacizumab without excessive dose modification cycle delay patient epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer .</brief_summary>
	<brief_title>Neoadjuvant Therapy Ovarian Cancer</brief_title>
	<detailed_description>This study design determine feasibility administer neoadjuvant carboplatin , paclitaxel , bevacizumab without excessive dose modification cycle delay patient epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer . This study also investigate rate optimal cytoreduction , response rate progression free overall survival , ass quality life patient epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer treat neoadjuvant carboplatin , paclitaxel bevacizumab .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must Suspected FIGO stage III IV disease . Cytologic histologic diagnosis carcinoma felt investigator compatible epithelial cancer ovary , fallopian tube , primary peritoneum Patients must GOG Performance Status 0 , 1 2 . Patients prior anthracycline exposure must baseline MUGA echocardiogram prior study entry . Patients must adequate : Bone marrow function : Absolute neutrophil count ( ANC ) great equal 1500/υl , equivalent Common Toxicity Criteria Adverse Events v3.0 ( CTCAE ) Grade 1 . This ANC induce support granulocyte colony stimulate factor . Platelets great equal 100,000/υl ( CTCAE Grade 01 ) . Hematocrit &gt; 21 % . Renal function : Creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) , CTCAE Grade 1 . Hepatic function : Bilirubin le equal 1.5 x ULN ( CTCAE Grade 1 ) . SGOT ( AST ) , SGPT ( ALT ) , alkaline phosphatase less equal 2.5 x ULN ( CTCAE Grade 1 ) . Neurologic function : Neuropathy ( sensory motor ) less equal CTCAE Grade 1 . Coagulation function : PT international normalize ratio ( INR ) ≤ 1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin management venous thrombosis include pulmonary thromboembolism ) PTT &lt; 1.2 time upper limit normal . Patients must measurable disease . Patients may may cancerrelated symptom . Baseline CA125 must ≥ 70 units/mL . Patients must meet preentry requirement . An approved informed consent authorization permit release personal health information must sign patient guardian . Eligible patient deem likely medically fit undergo surgical cytoreduction 3 cycle neoadjuvant chemotherapy surgical gynecologic oncologist . Patients may receive estrogen +/ progestin replacement . Patients NOT undergone prior cancer direct surgery ( exploration , debulking , etc ) , exception minor procedure biopsy cytology specimen . Patients receive prior chemotherapy , immunotherapy , radiotherapy , hormonal therapy biologic therapy ovarian primary peritoneal cancer eligible . Patients borderline ovarian tumor , recurrent epithelial ovarian primary peritoneal cancer nonepithelial ovarian cancer eligible . Patients CA125 : CEA ratio &lt; 25 . Patients cancer ( nonmelanoma skin cancer ) within last five year . Patients acute hepatitis end stage liver disease . Patients serious nonhealing wound , ulcer bone fracture . This include history abdominal fistula intraabdominal abscess within 6 month . Patients granulate incision heal secondary intention evidence fascial dehiscence infection eligible require weekly wound examination . History prior gastrointestinal perforation . Patients evidence abdominal free air explain paracentesis . Patients sign symptom gastrointestinal obstruction include receive total parenteral nutrition ( TPN ) , intravenous hydration tube feed . Patients active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel image , regardless whether chance require vascular reconstruction . Patients history evidence upon physical examination CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within six month first date treatment study . Patients treat brain metastasis enter study . Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude . Patients clinically significant cardiovascular disease . This include : Uncontrolled hypertension , define systolic &gt; 140 mm Hg diastolic &gt; 90 mm Hg . Myocardial infarction unstable angina within 6 month day 1 prior registration . New York Heart Association ( NYHA ) Grade II great congestive heart failure . Serious cardiac arrhythmia require medication . This include atrial fibrillation . CTCAE Grade 3 great peripheral vascular disease . History CVA within six month . Patients know hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody include hypersensitivity component bevacizumab Patients clinically significant proteinuria . Urine protein screen urine proteincreatinine ratio ( UPCR ) . The UPCR find correlate directly amount protein excreted 24 hour urine collection . Specifically , UPCR 1.0 equivalent 1.0 gram protein 24 hour urine collection . Obtain least 4 ml random urine sample sterile container ( 24 hour urine ) . Send sample lab request urine protein creatinine level ( separate request ) . The lab measure protein concentration ( mg/dL ) creatinine concentration ( mg/dL ) . The UPCR derive follow : protein concentration ( mg/dL ) /creatinine ( mg/dL ) . Patients must UPCR &lt; 1.0 allow participation study . Patients hypertensive crisis hypertensive encephalopathy History hemoptysis ( ≥ ½ teaspoon bright red blood per episode ) within 1 month prior day 1 . Patients anticipation nonstudy related invasive procedure define follow : Major surgical procedure , open biopsy significant traumatic injury within 28 day prior first date bevacizumab . Major nonstudy relate surgical procedure anticipate course study . Core biopsy within 7 day prior first date bevacizumab . Patients GOG Performance Status Grade 3 4 eligible . Patients pregnant nursing . Subjects childbearing age use effective mean contraception . Patients age 18 . Patients receive prior therapy antiVEGF drug , include bevacizumab . Patients human immunodeficiency virus ( HIV ) . Patients medical history condition otherwise previously specify opinion investigator exclude participation study . The investigator consult Study Chair .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>